文献速递消化系统肿瘤

IDEA数据库中早发性结直肠腺癌:3个月和6个月辅助氟尿嘧啶和奥沙利铂治疗的依从性、毒性及结局

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
PubMed 文献 · J Clin Oncol · 2021-11-09

基于IDEA数据库中六项试验的个体患者数据,比较早发性(<50岁)与晚发性(≥50岁)结直肠癌患者的治疗依从性、不良事件及癌症特异性结局。早发性患者依从性和剂量强度更高,但高危III期早发性患者3年无复发生存率更低(54% vs 65%),5年癌症特异性死亡率更高(24% vs 20%)。

要点

  • 早发性结直肠癌患者完成计划治疗的比例更高(83.2% vs 78.2%,P<.01)。
  • 高危III期早发性患者3年无复发生存率显著更低(54% vs 65%;HR 1.33;95%CI 1.14-1.55;P<.001)。
  • 该亚组中3个月与6个月治疗的无病生存率无显著差异(57% vs 56%;HR 0.97;95%CI 0.73-1.29;P=.85)。

核心结论

  • 年轻年龄在高危III期结直肠癌中为负面预后因素,与显著更高的复发率相关,尽管治疗依从性更好且给药强度更高,提示疾病生物学更具侵袭性。

研究设计与样本

  • 分析国际辅助化疗持续时间评估(IDEA)数据库中六项试验的个体患者数据,共16,349例患者,其中1,564例(9.6%)为早发性结直肠癌。

主要发现

  • 与晚发性结直肠癌相比,早发性患者体能状态更好(86% vs 80%,P<.01),T分期相似(T1-3/T4:76/24 vs 77/23,P=.97),N2疾病比例更高(24% vs 22%,P<.01),更可能完成计划治疗时长(83.2% vs 78.2%,P<.01),并接受更高的治疗剂量强度,尤其在6个月方案中。
  • 早发性患者胃肠道毒性更常见;晚发性患者血液学毒性更频繁。
  • 高危III期早发性患者与晚发性患者相比,3年无复发生存率更低(54% vs 65%;HR 1.33;95%CI 1.14-1.55;P<.001),5年癌症特异性死亡率更高(24% vs 20%;HR 1.21;95%CI 1.00-1.47;P<.06)。
  • 在高危III期早发性亚组中,3个月与6个月治疗的无病生存率无显著差异(57% vs 56%;HR 0.97;95%CI 0.73-1.29;P=.85)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on optimal adjuvant therapy should consider treatment adherence, adverse events, and expected outcomes in a population with life expectancy longer than later-onset (LO) CRC (age ≥ 50 years). MATERIALS AND METHODS: Individual patient data from six trials in the International Duration Evaluation of Adjuvant Chemotherapy database were analyzed. Characteristics, treatment adherence, and adverse events in stage II or III EO-CRC and LO-CRC were compared. To reduce confounders of non-cancer-related deaths because of age or comorbidities, time to recurrence (3-year relapse-free rate) and cancer-specific survival (5-year cancer-specific mortality rate) were considered. RESULTS: Out of 16,349 patients, 1,564 (9.6%) had EO-CRC. Compared with LO-CRC, EO-CRC had better performance status (86% v 80%, P < .01), similar T stage (% T1-3/T4: 76/24 v 77/23, P = .97), higher N2 disease rate (24% v 22%, P < .01), more likely to complete the planned treatment duration (83.2% v 78.2%, P < .01), and received a higher treatment dose intensity, especially with 6-month regimens. Gastrointestinal toxicity was more common in EO-CRC; hematologic toxicity was more frequent in LO-CRC. Compared with LO-CRC, significantly worse cancer-specific outcomes were demonstrated especially in high-risk stage III EO-CRC: lower 3-year relapse-free rate (54% v 65%; hazard ratio [HR] 1.33; 95% CI, 1.14 to 1.55; P value < .001) and higher 5-year cancer-specific mortality rate (24% v 20%; HR 1.21; 95% CI, 1.00 to 1.47; P value < .06). In this subgroup, no difference was observed with 3 or 6 months of therapy, with equally poor disease-free survival rates (57% v 56%; HR 0.97; 95% CI, 0.73 to 1.29; P value = .85). CONCLUSION: Young age is negatively prognostic in high-risk stage III CRC and associated with significantly higher relapse rate; this is despite better treatment adherence and higher administered treatment intensity, suggesting more aggressive disease biology.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fontana E, Meyers J, Sobrero A, et al. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. J Clin Oncol. 2021. PMID: 34752136. doi:10.1200/JCO.21.02008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。